Pro-life organization calls on HHS and FDA to suspend abortion pill approval, tighten safety rules
FIRST ON FOX: Live Action, a pro-life organization, is demanding that the Trump administration take action on the distribution of and reporting on mifepristone, often colloquially called "the abortion pill."...
By Fox News · Fox News
FIRST ON FOX: Live Action, a pro-life organization, is demanding that the Trump administration take action on the distribution of and reporting on mifepristone, often colloquially called "the abortion pill." The group is holding a press conference on Capitol Hill on Thursday to discuss concerns surrounding the abortion drug, as well as a new investigative video from Live Action that the group says documents "the dangerous real-world distribution of this drug by Planned Parenthood and affiliated providers." The group alleges "reckless distribution" practices and argues the adverse effects of the drug are not being documented properly, if at all. In a letter to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, Live Action said that it aims to show "clear evidence of regulatory noncompliance and patient harm" and to issue a call for immediate action from HHS and the FDA. The letter urges HHS and the FDA to suspend the approval of mifepristone, prohibit the distribution of abortion pills through mail-order services and telehealth, reinstate comprehensive adverse-event reporting requirements and release a full public accounting of the scientific and clinical evidence used to expand access to the drug . PRO-LIFE GROUPS WARN TRUMP HYDE AMENDMENT IS 'NON-NEGOTIABLE' AFTER FLEXIBILITY REMARKS "For more than two decades, mifepristone has remained on the market under an approval process that was politically accelerated, shielded from transparency, and repeatedly expanded without regard for patient safety, adverse event reporting, or statutory compliance," the letter, signed by Live Action Founder and President Lila Rose, reads. The FDA currently allows mifepristone to be prescribed via telehealth appointments and distributed by mail under its risk evaluation and mitigation strategy (REMS) program. The FDA advises against buying mifepristone online outside its REMS program, warning that th…